ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "antiphospholipid syndrome"

  • Abstract Number: 1606 • ACR Convergence 2023

    Purinergic Signaling as a Potential Therapeutic Target for APS Thromboinflammation

    NaveenKumar K. Somanathapura, Claire Hoy, Srilakshmi Yalavarthi, Cyrus Sarosh, Bruna De Moraes Mazetto Fonseca, Caroline Ranger, Christine Rysenga, Ajay Tambralli, Jacqueline Madison, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI

    Background/Purpose: In first responding cells such as neutrophils and platelets, extracellular ATP released from activated or dying cells engages cell-surface receptors to launch proinflammatory and…
  • Abstract Number: 0110 • ACR Convergence 2023

    Neutrophil Extracellular Traps as Mediators of Antiphospholipid Antibody-Induced Trophoblast Dysfunction and Fetal Loss

    Christine Rysenga, Srilakshmi Yalavarthi, Wenying Liang, Claire Hoy, Cyrus Sarosh, Richard Lieberman, Yu Zuo and Jason Knight, University of Michigan, Ann Arbor, MI

    Background/Purpose: Antiphospholipid antibodies (aPL) induce obstetric complications associated with placental insufficiency by promoting trophoblast dysfunction and inflammation at the maternal-fetal interface. Neutrophils have been found…
  • Abstract Number: 1607 • ACR Convergence 2023

    Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus

    Eduardo Gomez-Banuelos1, Alessandra Ida Celia2, Maria Isabel Trejo Zambrano3, Merlin Paz3, Erika Darrah3, Daniel Goldman4, Michelle Petri4 and Felipe Andrade3, 1The Johns Hopkins University, Baltimore, MD, 2John Hopkins University of Medicine, Rome, Italy, 3Johns Hopkins University, Baltimore, MD, 4Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Upon activation with interferon (IFN) and RNP-immune complexes, defective mitophagy in neutrophils results in the release of mtDNA in complex with transcription factor A…
  • Abstract Number: 0111 • ACR Convergence 2023

    Hippo-YAP1-CCN2 Signaling by Microvascular Endothelial Cells Licenses Vascular Smooth Muscle Cell Proliferation in Antiphospholipid Syndrome

    Wenying Liang1, Allison Billi1, Srilakshmi Yalavarthi1, Christine Rysenga1, Claire Hoy1, Cyrus Sarosh1, Yu Zuo1, Eliza Pei-Suen Tsou1, Jason Knight1 and Hui Shi2, 1University of Michigan, Ann Arbor, MI, 2Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    Background/Purpose: Some patients with antiphospholipid syndrome (APS) are afflicted by an insidious small-vessel vasculopathy that results in the accrual of organ damage over time. While…
  • Abstract Number: 1608 • ACR Convergence 2023

    Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry

    Ayesha Butt1, Rolando Garcia Milian1, George Goshua1, Sean Gu1, Eugenia Chock2, Valentina Restrepo1, John Hwa1, Hyung Chun1, H Michael Belmont3, Kello Nina4, D. Ware Branch5, Michelle Petri6, Jason Knight7, Rohan Willis8, Maria Laura Bertolaccini9, Doruk Erkan10, Alfred lee1, Anish Sharda1 and Alexander Pine11, 1Yale School of Medicine, New Haven, CT, 2Yale School of Medicine, Greenwich, CT, 3NYU School of Medicine, New York, NY, 4Northwell Health, Brooklyn, NY, 5University of Utah, Salt Lake City, UT, 6Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 7University of Michigan, Ann Arbor, MI, 8University of Texas Medical Branch, Galveston, TX, 9King's College London, London, United Kingdom, 10Hospital for Special Surgery, New York, NY, 11VA Connecticut/Yale School of Medicine, West Haven, CT

    Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…
  • Abstract Number: 0096 • ACR Convergence 2023

    Performance Assessment of Lupus Anticoagulant Tests Using Taipan and Ecarin Snake Venom Clotting Times: An International Study from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratories

    Maria Efthymiou1, Ian Mackie1, Rohan Willis2, Vittorio Pengo3, Danieli Andrade4, Elisa Bison3, Olga Amengual5, Zurina Romay-Penabad6, Yuichiro Fujieda5, Maria Laura Bertolaccini7, Doruk Erkan8, Hannah Cohen9 and On Behalf Of APS ACTION10, 1University College London, London, United Kingdom, 2University of Texas Medical Branch, Galveston, TX, 3Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, 4University of São Paulo, São Paulo, Brazil, 5Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan, 6Antiphospholipid Standardization Laboratory, Division of Rheumatology, University of Texas Medical Branch, TX, 7King's College London, London, United Kingdom, 8Hospital for Special Surgery, New York, NY, 9University College London Hospitals NHS Foundation Trust, London, United Kingdom, 10on behalf of APS ACTION, New York, NY

    Background/Purpose: Lupus anticoagulant (LA) test performance is critical for APS diagnosis and management. However, variability remains a challenge in LA testing, particularly in anticoagulated samples,…
  • Abstract Number: 0112 • ACR Convergence 2023

    Molecular Stratification of Antiphospholipid Syndrome Patients Through Integrative Analysis of the Whole-blood RNA Transcriptome

    Amala Ambati1, Feiyang Ma1, Katarina Kmetova1, Sherwin Navaz1, Claire Hoy1, Cyrus Sarosh1, Ajay Tambralli1, Johann E. Gudjonsson1, J. Michelle Kahlenberg1, Jacqueline Madison1, Ali Duarte-Garcia2, Jason Knight1 and Yu Zuo1, 1University of Michigan, Ann Arbor, MI, 2Mayo Clinic, Rochester, MN

    Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease associated with diverse clinical manifestations in the setting of persistent antiphospholipid antibodies (aPL). Early diagnosis and…
  • Abstract Number: 2324 • ACR Convergence 2023

    Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study

    Lixia Yao, Liwam Gebru, Biruk Aweke, Jay Patel, Ernest Vina, David Fleece and Huanmei Wu, Temple University, Philadelphia, PA

    Background/Purpose: Epidemiologists, health services researchers, and health outcome investigators have begun utilizing real-world data (RWD) to gain valuable insights into disease patterns, treatment outcomes, and…
  • Abstract Number: 0097 • ACR Convergence 2023

    Transient Ischemic Attack in Antiphospholipid Antibody-positive Patients: Retrospective and Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

    Zeynep Belce Erton1, Jonathan Thaler2, Danieli Andrade3, Megan Barber4, Maria Tektonidou5, Savino Sciascia6, Vittorio Pengo7, Jose Pardos-Gea8, Guillermo Ruiz-Irastorza9, Chary Lopez-Pedrera10, H Michael Belmont11, Kello Nina12, Paul R. Fortin13, Stéphane Zuily14, Cecilia Chighizola15, Flavio Victor Signorelli16, Zhuoli Zhang17, Tatsuya Atsuma18, Maria Efthymiou19, D. Ware Branch20, Cecilia Nalli21, Esther Rodriguez almaraz22, Michelle Petri23, Giulia Pazzola24, Ricard Cervera25, Bahar Artim Esen26, Hui Shi27, Yu Zuo28, Rosana M Quintana29, Rohan Willis30, Ali Duarte-Garcia31, Maria Laura Bertolaccini32, Hannah Cohen33, Doruk Erkan2 and On Behalf Of APS ACTION34, 1SUNY Downstate Medical Center, Brooklyn, NY, 2Hospital for Special Surgery, New York, NY, 3University of São Paulo, São Paulo, Brazil, 4University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 5Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, 6University of Turin, Torino, Italy, 7Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, 8Vall d'Hebron University Hospital, Barcelona, Spain, 9Hospital Universitario Cruces, Barakaldo, Spain, 10IMIBIC - Reina Sofia Hospital, Córdoba, Spain, 11NYU School of Medicine, New York, NY, 12Northwell Health, Brooklyn, NY, 13Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, 14Lorraine University, Vandoeuvre-lès-Nancy, France, 15University of Milan, Milan, Italy, 16University of São Paulo, Rio De Janeiro, Brazil, 17Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, 18Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, 19University College London, London, United Kingdom, 20University of Utah, Salt Lake City, UT, 21Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, 22Hospital Universitario 12 de Octubre, Madrid, Spain, 23Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 24Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, 25Hospital Clínic de Barcelona, Barcelona, Spain, 26Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 27Rijin Hospital, Shanghai, China, 28University of Michigan, Ann Arbor, MI, 29Centro Regional de Enfermedades Autoinmunes y Reumticas (CREAR), Grupo Oroño, Rosario, Argentina, 30University of Texas Medical Branch, Galveston, TX, 31Mayo Clinic, Rochester, MN, 32King's College London, London, United Kingdom, 33University College London Hospitals NHS Foundation Trust, London, United Kingdom, 34on behalf of APS ACTION, New York, NY

    Background/Purpose: APS ACTION Registry aims to study the course of disease in antiphospholipid antibody (aPL)-positive patients. Although transient ischemic attack (TIA) can develop in aPL-positive…
  • Abstract Number: 0113 • ACR Convergence 2023

    Serum Myeloperoxidase (MPO)-DNA Complexes and Serum Calprotectin Differentiate Isolated Thrombotic Antiphospholipid Syndrome from Isolated Obstetric Antiphospholipid Syndrome

    Ruyu Liang1, Ranran Yao2, Ziye Wang3, Wenwen Pei2, Renge Liang3 and Chun Li4, 1Peking University, XiCheng, China, 2Peking University, Beijing, China, 3Peking University People's Hospital, Beijing, China, 4Peking University People’s Hospital, Beijing, China

    Background/Purpose: There is a lack of serum markers to differentiate thrombotic APS (tAPS) and obstetric APS (oAPS). Neutrophil extracellular traps (NETs) are involved in the…
  • Abstract Number: 2454 • ACR Convergence 2023

    Endometriosis Increase Risk of Antiphospholipid Syndrome: A Propensity Score Matched Cohort Study

    Zhiyong Chen1, Shiow-Ing Wang2, James Cheng-Chung Wei3 and Sheng-Ming Dai1, 1Department of Rheumatology and Immunology, Shanghai Sixth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 2Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan, 3Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan

    Background/Purpose: Patients with endometriosis have a variety of autoimmune abnormalities. Our objective was to investigate the risk of incident antiphospholipid syndrome (APS) in patients with…
  • Abstract Number: 0098 • ACR Convergence 2023

    Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository “Registry”

    Yasaman Ahmadzadeh1, Larry Magder2, Zeynep Ozge Ozdemir3, Danieli Andrade4, Megan R.W. Barber5, Maria Tektonidou6, Savino Sciascia7, Vittorio Pengo8, Ariadna Anunciación-Llunell9, Guillermo Ruiz-Irastorza10, Mª Angeles Aguirre11, Michael Belmont12, Kello Nina13, Paul R. Fortin14, Denis WAHL15, Maria Gerosa16, Guilherme De Jesús17, Zhuoli Zhang18, Tatsuya Atsuma19, Maria Efthymiou20, D. Ware Branch21, Angela Tincani22, Esther Rodriguez almaraz23, Giulia Pazzola24, Ricard Cervera25, Bahar Artim Esen26, Hui Shi27, Jason Knight28, Guillermo Pons-Estel29, Rohan Willis30, Ali Duarte-Garcia31, Maria Laura Bertolaccini32, Hannah Cohen33, Michelle Petri34, Doruk Erkan35 and On Behalf Of APS ACTION36, 1Roger Williams Medical Center, Providence, RI, 2University of Maryland, Baltimore, MD, 3Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, 4University of São Paulo, São Paulo, Brazil, 5University of Calgary, Calgary, AB, Canada, 6Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, 7University of Turin, Torino, Italy, 8Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, 9VHIR Vall d'Hebron Institut de Investigación, Barcelona, Spain, 10Hospital Universitario Cruces, Barakaldo, Spain, 11Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, 12New York University Langone Medical Center, New York, NY, 13Northwell Health, Brooklyn, NY, 14Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, 15University of Lorraine, Nancy, France, 16University of Milan, Milano, Italy, 17Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 18Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, 19Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, 20University College London, London, United Kingdom, 21University of Utah, Salt Lake City, UT, 22Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Gussago, Italy, 23Hospital Universitario 12 de Octubre, Madrid, Spain, 24Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, 25Hospital Clínic de Barcelona, Barcelona, Spain, 26Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 27Rijin Hospital, Shanghai, China, 28University of Michigan, Ann Arbor, MI, 29CREAR, Rosario, Argentina, 30University of Texas Medical Branch, Galveston, TX, 31Mayo Clinic, Rochester, MN, 32King's College London, London, United Kingdom, 33Haemostasis Research Unit, Department of Hematology, University College London, London, United Kingdom, 34Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 35Hospital for Special Surgery, New York, NY, 36on behalf of APS ACTION, New York, NY

    Background/Purpose: APS ACTION "Registry" was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
  • Abstract Number: 0114 • ACR Convergence 2023

    Platelets Are Highly Activated and Could Participate in Immune Abnormality of APS

    Yu Shi1, Xiaofan Luo2, Quan Chen3, Jiuliang zhao4, Mengtao Li4 and xiaofeng Zeng5, 1Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Nankai University, Tianjin, China, 3Nankai University, Beijing, China, 4Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 5Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Platelets play a pivotal role in the process of coagulation and other biological process. Studies have shown multiple evidences that platelets are highly activated…
  • Abstract Number: 0099 • ACR Convergence 2023

    Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases

    Doruk Erkan1, JoAnn Vega1, Tyler O'Malley2 and Andrew Concoff3, 1Hospital for Special Surgery, New York, NY, 2Exagen, Vista, CA, 3Exagen, Los Angeles, CA

    Background/Purpose: Based on animal models, complement activation is part of Antiphospholipid Syndrome (APS) pathogenesis. However, studies investigating complement activation in antiphospholipid antibody (aPL)-positive patients are…
  • Abstract Number: 0115 • ACR Convergence 2023

    Risk Factors of First Thrombosis in Obstetric Antiphospholipid Syndrome

    liang luo1, Qingmeng Cai2, xiangjun liu2, Yuke Hou3 and Chun Li4, 1Department of Chinese Medicine, the People's Hospital of Yubei District of Chongqing City, Chongqing, China; Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 2Department of Rheumatology and Immunology, Peking University People's Hospital, Xicheng District, Beijing, China, 3Peking University People's Hospital, Beijing, China, 4Peking University People’s Hospital, Beijing, China

    Background/Purpose: Limited evidence exists regarding the long-term risk of thrombosis in patients with obstetric antiphospholipid syndrome (OAPS). This study aimed to investigate the clinical features…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology